Loading organizations...
Key people at C-Bridge.
C-Bridge is a Boston, Massachusetts-based technology firm that provides electronic services, strategy, design, implementation, and training for business-to-business eCommerce applications. During its operational history as an independent entity, the enterprise successfully secured $9.9 million in total venture funding to scale its digital supply chain and enterprise integration solutions. The firm's corporate trajectory culminated in a strategic acquisition by eXcelon, a data management software provider, in 2001. Its executive alumni network includes notable industry figures such as Rick Farnell, who subsequently served as the chief executive officer of digital risk protection company Appdetex. The broader C-Bridge brand name is also utilized by distinct corporate entities, including an international mining supply chain provider established in 2008 and a specialized investment advisor compliance consultancy. The original Boston-based technology organization was officially founded in 1996 by its initial management team.
CBC Group (formerly C-Bridge Capital) is Asia's largest healthcare-dedicated asset management firm, headquartered in Singapore with a focus on private investments in healthcare and biotechnology.[1][4] Its mission centers on an "investor-operator" approach that combines capital deployment with operational expertise to drive innovation in pharmaceuticals, biotech, medtech, and healthcare services, primarily targeting late-stage companies with proven products while also supporting startups.[1][4] The firm invests across China, Singapore, Taiwan, Hong Kong, the US, and beyond, emphasizing minority stakes, business incubation, and strategies like bringing approved products from developed markets to Asia; it manages diverse funds including private equity, private credit (e.g., $300M R-Bridge Healthcare Fund), and infrastructure (up to $1.5B with $400M seed from APG).[1][3] CBC has significantly impacted Asia's startup ecosystem by backing high-potential healthcare ventures, enabling clinical advancements, market expansions, and infrastructure builds, as seen in deals like the $680M acquisition of UCB's China business with Mubadala.[1]
Founded in 2014 as C-Bridge Capital in Shanghai, CBC targeted private equity in China's healthcare sector, partially backed by Temasek Holdings.[1] Key figures include CEO Wei Fu, who has led global expansion efforts, and Peng Fu, involved in deal sourcing for private credit initiatives.[3] The firm evolved from a China-centric minority investor in startups to a broader "investor-operator" model, rebranding to CBC Group and relocating headquarters to Singapore; it expanded geographically to offices in Shanghai, Beijing, Hong Kong, New York, and Seoul, while diversifying into private credit (2020), SPACs (2021 Nasdaq listing via Summit Healthcare Acquisition raising $200M), and infrastructure funds (2021).[1][3] Pivotal moments include launching its first private credit fund and high-profile acquisitions, solidifying its position as Asia's top healthcare investor.[1]
CBC rides the wave of Asia's booming healthcare and biotech sector, fueled by aging populations, rising R&D in China, and post-pandemic demand for innovation in pharmaceuticals and medtech.[1][3] Timing is ideal amid China's push for self-reliant biotech amid global supply chain shifts, with CBC facilitating Western tech transfers to Asia via its expansion strategy.[1] Market forces like increased private credit needs and infrastructure gaps in life sciences favor its diversified funds, positioning it as a bridge between mature markets (US/Europe) and high-growth Asia.[3] The firm influences the ecosystem by empowering startups through incubation, enabling scale-ups, and fostering a "one-stop" asset management hub, as evidenced by plans for international offices and funds targeting North America/Europe.[3]
CBC Group is poised for global dominance in healthcare investing, with recent fundraises (e.g., third healthcare fund targeting $650M) and office expansions signaling a shift from China focus to a comprehensive platform.[3] Trends like AI-driven drug discovery, personalized medicine, and Asia's infrastructure buildout will shape its trajectory, amplifying its operator edge amid regulatory easing in biotech hubs.[1][3] Its influence may evolve into a full-spectrum player rivaling Western giants, potentially through more SPACs, credit vehicles, and cross-continental portfolios—cementing its role as the go-to "investor-operator" for healthcare's next frontier.[3][4]
Key people at C-Bridge.
